Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

CCL2 mobilizes ALIX to facilitate Gag-p6 mediated HIV-1 virion release.

Ajasin DO, Rao VR, Wu X, Ramasamy S, Pujato M, Ruiz AP, Fiser A, Bresnick AR, Kalpana GV, Prasad VR.

Elife. 2019 Jun 7;8. pii: e35546. doi: 10.7554/eLife.35546.

2.

FISHing Out the Hidden Enemy: Advances in Detecting and Measuring Latent HIV-Infected Cells.

Prasad VR, Kalpana GV.

MBio. 2017 Sep 19;8(5). pii: e01433-17. doi: 10.1128/mBio.01433-17.

3.

An Essential Role of INI1/hSNF5 Chromatin Remodeling Protein in HIV-1 Posttranscriptional Events and Gag/Gag-Pol Stability.

La Porte A, Cano J, Wu X, Mitra D, Kalpana GV.

J Virol. 2016 Oct 14;90(21):9889-9904. doi: 10.1128/JVI.00323-16. Print 2016 Nov 1.

4.

Computational modeling of Repeat1 region of INI1/hSNF5: An evolutionary link with ubiquitin.

Bhutoria S, Kalpana GV, Acharya SA.

Protein Sci. 2016 Sep;25(9):1593-604. doi: 10.1002/pro.2961. Epub 2016 Jun 27.

5.

Quantification of HIV-1 Gag Localization Within Virus Producer Cells.

La Porte A, Kalpana GV.

Methods Mol Biol. 2016;1354:165-74. doi: 10.1007/978-1-4939-3046-3_11.

PMID:
26714711
6.

Dopamine receptor activation increases HIV entry into primary human macrophages.

Gaskill PJ, Yano HH, Kalpana GV, Javitch JA, Berman JW.

PLoS One. 2014 Sep 30;9(9):e108232. doi: 10.1371/journal.pone.0108232. eCollection 2014.

7.

INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo.

Mathew S, Nguyen M, Wu X, Pal A, Shah VB, Prasad VR, Aiken C, Kalpana GV.

Retrovirology. 2013 Jun 24;10:66. doi: 10.1186/1742-4690-10-66.

8.

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.

Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.

9.

In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.

Smith ME, Das BC, Kalpana GV.

Cancer Cell Int. 2011 Sep 27;11:34. doi: 10.1186/1475-2867-11-34.

10.

Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV.

Cancer Res. 2011 May 1;71(9):3225-35. doi: 10.1158/0008-5472.CAN-10-2167. Epub 2011 Apr 26.

11.

Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.

Smith ME, Cimica V, Chinni S, Jana S, Koba W, Yang Z, Fine E, Zagzag D, Montagna C, Kalpana GV.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):319-24. doi: 10.1073/pnas.0913297108. Epub 2010 Dec 20.

12.

Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative mutant S6.

Cano J, Kalpana GV.

J Virol. 2011 Mar;85(5):2254-65. doi: 10.1128/JVI.00006-10. Epub 2010 Dec 15.

13.

Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Cimica V, Smith ME, Zhang Z, Mathur D, Mani S, Kalpana GV.

BMC Cancer. 2010 Nov 19;10:634. doi: 10.1186/1471-2407-10-634.

14.

Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication.

Sorin M, Cano J, Das S, Mathew S, Wu X, Davies KP, Shi X, Cheng SW, Ott D, Kalpana GV.

PLoS Pathog. 2009 Jun;5(6):e1000463. doi: 10.1371/journal.ppat.1000463. Epub 2009 Jun 5.

15.

Multimerization and DNA binding properties of INI1/hSNF5 and its functional significance.

Das S, Cano J, Kalpana GV.

J Biol Chem. 2009 Jul 24;284(30):19903-14. doi: 10.1074/jbc.M808141200. Epub 2009 Apr 27.

16.

Reverse two-hybrid screening to analyze protein-protein interaction of HIV-1 viral and cellular proteins.

Das S, Kalpana GV.

Methods Mol Biol. 2009;485:271-93. doi: 10.1007/978-1-59745-170-3_19.

PMID:
19020832
17.

Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.

Xu Z, Zheng Y, Ao Z, Clement M, Mouland AJ, Kalpana GV, Belhumeur P, Cohen EA, Yao X.

Retrovirology. 2008 Nov 14;5:102. doi: 10.1186/1742-4690-5-102.

18.

Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.

Das BC, Smith ME, Kalpana GV.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4177-80. doi: 10.1016/j.bmcl.2008.05.097. Epub 2008 May 29.

PMID:
18556204
19.

Design and synthesis of 4-HPR derivatives for rhabdoid tumors.

Das BC, Smith ME, Kalpana GV.

Bioorg Med Chem Lett. 2008 Jul 1;18(13):3805-8. doi: 10.1016/j.bmcl.2008.05.021. Epub 2008 May 9.

PMID:
18515102
20.

Rhabdoid tumor growth is inhibited by flavopiridol.

Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV.

Clin Cancer Res. 2008 Jan 15;14(2):523-32. doi: 10.1158/1078-0432.CCR-07-1347.

21.

The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor.

Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, Parks DJ, Collins JL, Willson TM, Kalpana GV, Venkatesh M, Xie W, Cho SY, Roboz J, Redinbo M, Moore JT, Mani S.

Mol Endocrinol. 2008 Apr;22(4):838-57. Epub 2007 Dec 20.

22.

INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors.

Morozov A, Lee SJ, Zhang ZK, Cimica V, Zagzag D, Kalpana GV.

Clin Cancer Res. 2007 Aug 15;13(16):4721-30.

23.

HIV-1 replication in cell lines harboring INI1/hSNF5 mutations.

Sorin M, Yung E, Wu X, Kalpana GV.

Retrovirology. 2006 Aug 31;3:56.

24.

Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole.

Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S.

Oncogene. 2007 Jan 11;26(2):258-68. Epub 2006 Jul 3.

PMID:
16819505
25.

Dynamics of virus-host interplay in HIV-1 replication.

Sorin M, Kalpana GV.

Curr HIV Res. 2006 Apr;4(2):117-30. Review.

PMID:
16611052
26.

Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.

Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV.

Oncogene. 2006 Feb 2;25(5):722-34.

PMID:
16302003
27.

Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.

Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV.

Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12129-34. Epub 2005 Aug 12.

28.

Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins.

Hehl EA, Joshi P, Kalpana GV, Prasad VR.

J Virol. 2004 May;78(10):5056-67.

29.

Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance.

Yung E, Sorin M, Wang EJ, Perumal S, Ott D, Kalpana GV.

J Virol. 2004 Mar;78(5):2222-31.

30.

Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.

Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV.

Mol Cell Biol. 2002 Aug;22(16):5975-88.

31.

A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis.

Craig E, Zhang ZK, Davies KP, Kalpana GV.

EMBO J. 2002 Jan 15;21(1-2):31-42.

32.

Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications.

Ghosh SS, Sappal BS, Kalpana GV, Lee SW, Chowdhury JR, Chowdhury NR.

J Biol Chem. 2001 Nov 9;276(45):42108-15. Epub 2001 Aug 23.

33.

Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1.

Yung E, Sorin M, Pal A, Craig E, Morozov A, Delattre O, Kappes J, Ott D, Kalpana GV.

Nat Med. 2001 Aug;7(8):920-6.

PMID:
11479624
34.

Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase.

Kalpana GV, Reicin A, Cheng GS, Sorin M, Paik S, Goff SP.

Virology. 1999 Jul 5;259(2):274-85.

35.

Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA.

Lee D, Sohn H, Kalpana GV, Choe J.

Nature. 1999 Jun 3;399(6735):487-91.

PMID:
10365963
36.

Retroviral vectors for liver-directed gene therapy.

Kalpana GV.

Semin Liver Dis. 1999;19(1):27-37. Review.

PMID:
10349681
37.

c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function.

Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV.

Nat Genet. 1999 May;22(1):102-5.

PMID:
10319872
38.
40.

Purification and biochemical heterogeneity of the mammalian SWI-SNF complex.

Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR.

EMBO J. 1996 Oct 1;15(19):5370-82.

41.
42.

The Drosophila snr1 and brm proteins are related to yeast SWI/SNF proteins and are components of a large protein complex.

Dingwall AK, Beek SJ, McCallum CM, Tamkun JW, Kalpana GV, Goff SP, Scott MP.

Mol Biol Cell. 1995 Jul;6(7):777-91.

43.

Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.

Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP.

Science. 1994 Dec 23;266(5193):2002-6.

PMID:
7801128
44.

Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc.

Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K.

Science. 1993 Dec 17;262(5141):1889-92.

PMID:
8266081
45.
46.

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.

Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP.

Cell. 1993 Jun 18;73(6):1067-78.

PMID:
8513493
47.

Insertional mutagenesis and illegitimate recombination in mycobacteria.

Kalpana GV, Bloom BR, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5433-7.

48.

Genetic systems for mycobacteria.

Jacobs WR Jr, Kalpana GV, Cirillo JD, Pascopella L, Snapper SB, Udani RA, Jones W, Barletta RG, Bloom BR.

Methods Enzymol. 1991;204:537-55. Review. No abstract available.

PMID:
1658570
49.

Inhibition of mevalonate kinase by disulphide compounds.

Lalitha R, Kalpana GV, Ramasarma T.

Indian J Biochem Biophys. 1986 Aug;23(4):204-7. No abstract available.

PMID:
3032775

Supplemental Content

Loading ...
Support Center